Article Text

other Versions

PDF
A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone.
  1. Cecile Grootscholten (m.grootscholten{at}aig.umcn.nl)
  1. Radboud University Nijmegen Medical Centre, Netherlands
    1. Jürgen W.C. Dieker (j.dieker{at}ibmc.u-strasbg.fr)
    1. Radboud University Nijmegen Medical Centre, Netherlands
      1. Fabian D. McGrath (f.d.mcgrath{at}lumc.nl)
      1. Leiden University Medical Centre, Netherlands
        1. Anja Roos (a.roos{at}lumc.nl)
        1. Leiden University Medical Centre, Netherlands
          1. Ronald H.W.M. Derksen (r.h.w.m.derksen{at}umcutrecht.nl)
          1. University Medical Centre Utrecht, Netherlands
            1. Johan van der Vlag (j.vandervlag{at}nier.umcn.nl)
            1. Radboud University Nijmegen Medical Centre, Netherlands
              1. Mohamed R. Daha (m.r.daha{at}lumc.nl)
              1. Leiden University Medical Centre, Netherlands
                1. Jo H.M. Berden (j.berden{at}nier.umcn.nl)
                1. Radboud University Nijmegen Medical Centre, Netherlands

                  Abstract

                  Objective: To study the prevalence and course of anti-chromatin (anti-nucleosome, anti-dsDNA and anti- histone)and anti-C1q autoantibodies in patients with proliferative lupus nephritis (LN), treated in a randomised controlled trial with either cyclophosphamide or azathioprine plus methylprednisolone.

                  Methods: Autoantibody levels were measured and analysed in 52 patients with proliferative LN, during their first year of treatment. Levels in both treatment arms were compared and associations with clinical, serological, and outcome parameters were studied.

                  Results: At study entry, prevalences for anti- nucleosome, anti-dsDNA, anti-histone and anti-C1q autoantibodies were 81%, 96%, 23% and 65%, respectively. Anti-chromatin autoantibodies correlated with each other, but not with anti-C1q levels. If patients were divided for their autoantibody titre at start of treatment above or below the median, the only significant differences were higher SLEDAI with higher anti-nucleosome, and higher creatinine with higher anti- C1q autoantibodies. During the first year a comparable rapid decline in the levels of anti-nucleosome, anti- dsDNA and anti-C1q autoantibodies was seen in both treatment arms. Anti-histone autoantibody levels were low and did not change. Renal flares were not preceded by rises in autoantibody titres.

                  Conclusions: These results indicate that measurement of anti-chromatin and anti-C1q autoantibodies is useful for diagnosing LN, but not for monitoring disease course.

                  • C1q
                  • autoantibodies
                  • chromatin
                  • lupus nephritis
                  • nucleosome

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.